Real-time
Euronext Amsterdam
10:08:00 2024-04-23 am EDT
5-day change
1st Jan Change
0.912
EUR
+1.33%
-5.36%
-11.74%
Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden
January 12, 2023 at 03:20 pm EST
BlackRock Inc. - Pharming Group N.V. - Leiden
BlackRock Inc. - Pharming Group N.V. - Leiden
Below you will find information from the register substantial holdings and gross short positions. The information has been provided by the organisation.
Date of transaction 11 jan 2023
Person obliged to notify BlackRock Inc.
Issuing institution Pharming Group N.V.
Registration Chamber of Commerce 28048592
Place of residence Leiden
Previous result
Next result
Distribution in numbers
Type of share
Number of shares
Number of voting rights
Capital interest
Voting rights
Manner of disposal
Settlement
Type of share Contract for difference
Number of shares 248.817,00
Number of voting rights 425.860,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement In contanten
Type of share Gewoon aandeel
Number of shares 1.338.887,00
Number of voting rights 1.338.887,00
Capital interest Potentieel
Voting rights Potentieel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement Fysieke levering
Type of share Gewoon aandeel
Number of shares 19.271.063,00
Number of voting rights 19.570.065,00
Capital interest Reëel
Voting rights Reëel
Manner of disposal Middellijk
(BlackRock, Inc.)
Settlement
Distribution in percentages
Type
Total holding
Directly real
Directly potential
Indirectly real
Indirectly potential
Type Kapitaalbelang
Total holding 3,18 %
Directly real 0,00 %
Directly potential 0,00 %
Indirectly real 2,94 %
Indirectly potential 0,24 %
Type Stemrecht
Total holding 3,25 %
Directly real 0,00 %
Directly potential 0,00 %
Indirectly real 2,98 %
Indirectly potential 0,27 %
Date last update: 12 January 2023
Disclaimer
Pharming Group NV published this content on 11 January 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 12 January 2023 20:19:05 UTC .
Pharming Group to Buy Back EUR123 Million of Bonds due 2025
Apr. 22
MT
Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds
Apr. 18
MT
Pharming Group N.V. announced that it expects to receive ?100 million in funding
Apr. 17
CI
Pharming Group N.V. Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib
Apr. 08
CI
Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of its Treatment for Rare Auto-Immune Disorder
Apr. 08
MT
Pharming Group N.V. Provides Earnings Guidance for the Year 2024
Mar. 14
CI
Pharming Group Seeks Acquisitions
Mar. 14
CI
Transcript : Pharming Group N.V., Q4 2023 Earnings Call, Mar 14, 2024
Mar. 14
Pharming Group N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 14
CI
Pharming Group N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 14
CI
RBC Raises Price Target on Pharming Group to EUR2.10 From EUR1.95, Keeps Outperform Rating
Jan. 09
MT
Pharming Group Announces Development Plans for Leniolisib for Additional Primary Immunodeficiencies
Dec. 15
CI
Pharming Group Plans Phase 2 Trial for Immune System Drug in 2024
Dec. 13
MT
Pharming Group Plans to Develop Leniolisib for Additional Primary Immunodeficiencies Following Engagement With FDA
Dec. 13
MT
Pharming Group Expects EU Panel Opinion in 2024 for Rare Immunodeficiency Treatment
Nov. 10
MT
Transcript : Pharming Group N.V., Q3 2023 Earnings Call, Oct 26, 2023
23-10-26
Pharming Group N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-26
CI
Pharming Group N.V. Appoints Richard Peters as Non-Executive Director
23-09-25
CI
Transcript : Pharming Group N.V. - Shareholder/Analyst Call
23-09-25
ADRs Advance, Warrantee Inc. Climbs 20.0%
23-09-22
DJ
ADRs Close Lower; Quantasing Group Ltd. Declines 33.5%
23-09-21
DJ
Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan
23-08-09
CI
Pharming Seeks Acquisitions
23-08-03
CI
Transcript : Pharming Group N.V., Q2 2023 Earnings Call, Aug 03, 2023
23-08-03
Pharming Group N.V. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-03
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.
Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.
More about the company
Average target price
2
EUR
Spread / Average Target
+122.22%
Consensus
1st Jan change
Capi.
-11.74% 645M +26.11% 659B +26.72% 557B -4.92% 359B +17.02% 322B +9.15% 297B +6.34% 215B +5.22% 210B -5.97% 200B -8.51% 149B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1